Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q86VK4
UPID:
ZN410_HUMAN
Alternative names:
Another partner for ARF 1
Alternative UPACC:
Q86VK4; B4DDV5; B4DR78; O00153; Q9BQ19
Background:
Zinc finger protein 410 (ZNF410) functions as a transcription factor, binding specifically to silence fetal hemoglobin expression in adult erythroid cells. It activates CHD4, repressing fetal hemoglobin genes HBG1 and HBG2, and may influence matrix-remodeling and gap junction genes, highlighting its role in gene regulation.
Therapeutic significance:
Understanding the role of Zinc finger protein 410 could open doors to potential therapeutic strategies, particularly in manipulating hemoglobin expression for treating hemoglobinopathies.